GlassScriptPhysician profile
David Hofman
NPI 1760190326
$3,504.71
in general payments reported to CMS, 2019-2025
24 companies · $1,518 in 2025
The $1,518 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $866 · 2024: $1,120 · 2025: $1,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,504.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $435.88 | 2023-2025 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $384.21 | 2023-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $328.55 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $283.46 | 2023-2025 | Eliquis, Camzyos |
| Tactile Systems Technology INC | $272.85 | 2023 | Entre Plus, Flexitouch Plus |
| Novo Nordisk INC | $257.44 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Aop Health US, LLC | $256.15 | 2025 | Rapiblyk |
| Janssen Pharmaceuticals, INC | $186.92 | 2023-2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $132.50 | 2023-2024 | Inpefa |
| Amgen INC. | $130.13 | 2023-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.16 | 2023-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $110.93 | 2024-2025 | Assure Wcd |
| Pfizer INC. | $109.94 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $89.36 | 2023-2025 | Verquvo |
| Scpharmaceuticals INC. | $84.92 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $59.77 | 2024-2025 | Watchman Access System, Watchman Flx |
| W. L. Gore & Associates, INC. | $49.51 | 2023 | Gore Viabahn Endoprosthesis |
| Regeneron Healthcare Solutions, INC. | $46.85 | 2023-2025 | Evkeeza, Praluent |
| Alnylam Pharmaceuticals INC. | $38.07 | 2025 | Amvuttra |
| Inspire Medical Systems, INC. | $36.00 | 2023 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $29.84 | 2025 | |
| Chiesi USA, INC. | $18.97 | 2025 | Juxtapid |
| Esperion Therapeutics, INC. | $18.95 | 2024 | Nexletol |
| Azurity Pharmaceuticals, INC. | $15.35 | 2023 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hofman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.